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A b s t r a c t 
Background: Arterial hypertension is one of the most common chronic diseases in the western world, affecting more than 
25% of the adult population.
Aim: The aim of this study was to assess changes in arterial blood pressure (BP) levels in hypertensive patients, after ablation 
of nerve terminals in renal arteries, using radiofrequency energy during 24 months of follow-up. 
Methods: Thirty-two patients with diagnosed resistant hypertension (20 men and 12 women) underwent percutaneous 
catheter-based renal denervation of nerve terminals in renal artery walls. Mean BP value before ablation was [mm Hg]:  
systolic 174.92, diastolic 99.73 and pulse pressure 75.19. After procedure reduction value of BP was reported [mm Hg]: systolic  
146.78; diastolic 87.14, pulse pressure 59.64 at 24-month follow-up (p < 0.05 for all). 
Results: 30% of patients had systolic BP ≤ 140 mm Hg, 67% had diastolic BP ≤ 90 mm Hg, and optimum BP values  
≤ 140/90 mm Hg were observed in 30% of patients. 
Conclusions: In our cohort of patients, percutaneous renal artery ablation procedure effectively reduces systolic, diastolic 
BP and pulse pressure. No adverse events during 24 months of follow-up were noted. These results were comparable with 
available data from SIMPLICITY I and II trials. 
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INTRODUCTION
There is an increasing prevalence of arterial hypertension 
— nearly 26% of the world’s adult population (nearly one 
billion people) suffer from arterial hypertension [1]. High 
blood pressure (BP) is the main risk factor for cardiovascular 
disease, renal failure, stroke, and myocardial infarction [2, 3]. 
Unfortunately, improvement in hypertension awareness, 
treatment, and control is not optimal [4]. Recent data have 
confirmed that only 74.9% of patients with arterial hyperten-
sion undergo treatment. In this group of patients, hypertension 
is well-controlled only in 52.5% of patients, suggesting that in 
up to a half of patients BP is uncontrolled [3].
Resistant hypertension is defined as BP that remains above 
the goal despite concurrent use of three antihypertensive 
medications (including diuretic) in optimal doses. Resistant 
hypertension is a severe clinical problem because it is difficult 
to treat and occurs in 10–12% of hypertensive patients [5–8]. 
Due to that fact new therapeutic options are needed. One 
of the effective and safe therapeutic methods for reduction 
of a high BP is percutaneous renal sympathetic denervation 
(RN). SYMPLICITY HTN-1 and SYMPLICITY HTN-2 studies 
testing this method proved significant reduction in BP lev-
els without major adverse outcomes [9–13]. However, the 
SYMPLICITY HTN-3 study did not confirm those findings, due 
to a specific patient subset attending the study (for example 
African American). 
The aim of this study was to assess changes in arterial BP 
levels in hypertensive patients after ablation of nerve terminals 
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in renal arteries (denervation) as well as procedure safety in 
two years of follow-up of patients in the Polish population.
METHODS
All patients were the part of the HTN-1 and HTN-2 stud-
ies. Adult patients with resistant arterial hypertension, who 
met all inclusion/exclusion criteria (Table 1) were eligible for 
this study. Basically, we included patients with diagnosed 
arterial hypertension resistant to pharmacological treatment. 
The presence of resistant arterial hypertension was defined as 
mean brachial artery seated systolic pressure above 160 mm Hg 
during out-patient department visits, despite historical com-
pliance with at least three antihypertensive drugs (including 
a diuretic) in optimal doses. 
Blood pressure measurement was performed in ac-
cordance with Joint National Committee 7 guidelines [14]. 
Measurements were performed each time by the same person, 
sitting, in triplicate, and then averaged. 
Four weeks before renal denervation mean BP systolic 
value was above 160 mm Hg. Also, four weeks before proce-
dure and during the entire study no modification of pharma-
cotherapy was allowed. Patient compliance with medication 
was strictly verified by interview and patient diary. In case of 
pharmacotherapy modification, patients were excluded from 
the follow-up analysis. Obesity was defined as waist circumfer-
ence > 102 cm in men, > 88 cm in women. 
The technique of renal denervation has recently been 
described [10–13]. After standard femoral vascular access, the 
SIMPLICITY catheter (Ardian Inc., USA, currently Medtronic 
Inc., USA) was introduced into each renal artery. During the 
procedure, a standard dose of unfractionated heparin was 
used. Six radiofrequency ablations at 8 W with duration up 
to 120 s each were performed in both renal arteries. Applied 
energy, tip temperature, and impedance were monitored by 
catheter system in response to a predetermined algorithm 
during the procedure. 
Follow-up visits were performed at one, three, six, nine, 
12, 18, and 24 months after the procedure. BP (systolic, 
diastolic, pulse pressure) measurements were performed (ac-
cording to the methodology described earlier), as well as blood 
count, electrolytes, urea, creatinine and urine, and a physical 
exam including orthostatic BP measurements.
During the entire study major adverse events (death, 
stroke, myocardial infarction) or other outcomes associated 
with the procedure were monitored.
Before the study, written informed consent was obtained 
from all patients. The study was approved by the Institutional 
Bioethics Committee (two separate ethics committee approv-
als since the patients attended in the SYMPLICITY HTN-1 and 
SYMPLICITY HTN-2 studies).
Statistical analysis 
For statistical analysis, we assessed continuous variables be-
tween groups, including the BP, with Student’s two-sample 
t test. All statistics analyses were performed with Statistica 
(StatSoft). Statistical significance was set at p = 0.05. All tests 
were two-tailed.
RESULTS
Thirty-two patients (20 men and 12 women) were included 
into the study. Baseline characteristics are presented in Table 2. 
Pre-procedure antihypertensive medications are presented in 
Table 1. Inclusion/exclusion criteria
1. Renal artery anomalies: 
a. Haemodynamically significant renal artery stenosis (over 50%) by visual assessment 
b. Atherosclerotic lesion or stenosis within the artery which may potentially, according to the operator, add additional hazard to patient 
safety during artery catheterisation 
c. Haemodynamically or physiologically significant stenosis that may be responsible for arterial hypertension 
d. Prior renal artery stenting or angioplasty 
e. Patients with more than one renal artery at one side 
2. Suspicion of secondary hypertension or diagnosed secondary hypertension regardless of the underlying cause (including one associated 
with administered drugs) 
3. Patients with a history of coronary artery disease manifested by myocardial infarction, unstable angina or stroke in the previous six months 
4. Patients with significant valvular disease 
5. Type 1 diabetes 
6. Patients with implantable cardioverter-defibrillator or pacemaker 
7. Patients requiring breathing support 
8. Patients suffering from a disease or taking drugs that potentially influence the effectiveness of the therapy (e.g. peripheral atherosclerosis, 
aortic aneurysm, bleeding disorders, thrombocytopenia, anaemia, arrhythmia, alcohol abuse, drug addiction) 
9. Patients who plan pregnancy or are pregnant
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Table 3. Patients’ ages ranged from 31 to 76 years (mean value 
56.75 years), and body mass index ranged from 23.36 to 
46.81 kg/m2 (33.21 kg/m2). The hypertension risk factors 
were: hypercholesterolaemia was diagnosed in 19 patients, 
diabetes mellitus type 2 in 11 patients, and obesity (waist 
circumference > 102 cm in men, > 88 cm in women) was 
present in nine patients. The co-existing cardiovascular 
disease included: seven patients had coronary artery dis-
ease, two patients had valvular disease, two patients had 
cardiomyopathy, and one patient had ventricular arrhyth-
mia. One patient had asthma, one had chronic obstructive 
pulmonary disease, and three patients had gastric ulcer. 
Only two patients were diagnosed with chronic renal insuf-
ficiency according to elevated creatinine and urea in blood 
serum (third grade according to classification, which means 
eGFR 30–59 mL/min/1.73 m2). No patient had symptoms 
of peripheral artery disease. Patients ranged by New York 
Heart Association classification from 1 to 3.
The mean value of three measurements of BP before 
ablation was: systolic from 162 to 212 mm Hg (mean value 
174.92 mm Hg), diastolic from 82 to 121 mm Hg (mean 
value 99.7 mm Hg), pulse pressure from 54 to 100 mm Hg 
(mean value 75.2 mm Hg). The heart rate ranged from 60 to 
98 bpm (mean value 72.3 bpm) (Table 2).
Periprocedural 
According to the protocol, six radiofrequency ablations at 
8 W lasting up to 120 s each were performed in both renal 
Table 2. Baseline characteristics
Patient numbers 32 (20 men, 12 women)
Age (mean) [years] 31–76 (56.75)
Weight (mean) [kg] 74–145 (94.91)
Height (mean) [cm] 159–184 (169)
Body mass index (mean) [kg/m2] 23.36–46.81 (33.21)
Risk factors:
Hypercholesterolaemia 19 (59%)
Diabetes mellitus 11 (34%)
Abdominal obesity (WC > 102 cm  
in men, 88 > cm in women)
9 (28%)
Current smoking 2 (6%)
Cardiovascular disease:
Heart failure (mean), NYHA grade 1–3
Angina pectoris 7 (22%)
Coronary artery disease 8 (25%)
Myocardial infraction 5 (16%)
Valvular disease 2 (6%)
Cardiomyopathy 2 (6%)
Ventricular arrhythmia 1 (3%)
Other disease:
Renal insufficiency 2 (6%)
Asthma 1 (3%)
Chronic obstructive pulmonary disease 1 (3%)
Gastric ulcer 3 (9%)
NYHA — New York Heart Association scale; WC — waist circumference
Table 3. Pre-procedure antihypertensive medications
Medications N %
Beta-blockers: 25 81%
acebutolol 1 3%
betaxolol 10 32%
bisoprolol 10 32%
carvedilol 1 3%
metoprolol 1 3%
nebivolol 1 3%
sotalol 1 3%
ACEI: 19 61%
captopril 3 10%
lisinopril 1 3%
cilazapril 1 3%
enalapril 2 6%
perindopril 1 3%
quinapril 6 19%
ramipril 4 13%
trandolapril 1 3%
ARB: 19 61%
candesartan 10 32%
losartan 2 6%
telmisartan 3 10%
valsartan 4 13%
amlodipine 10 32%
doxazosin 3 10%
clonidine 1 3%
rilmenidine 2 6%
nitrendipine 12 39%
dilitazem 3 10%
Diuretics: 46 –
chlortalidone 4 13%
spironolactone 13 42%
furosemide 11 35%
torasemide 7 23%
hydrochlorothiazide 5 16%
indapamide 4 13%
amiloride 2 6%
ACEI — angiotensin-converting-enzyme inhibitors; ARB — angioten-
sin II receptor antagonists; beta-blockers — beta adrenergic receptor 
antagonists
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arteries in each patient. No complications related to vascular 
access site or other adverse events like vascular, renal, or 
cardiovascular complications were noted. Visceral pain at 
the time of energy delivery was managed mostly with sup-
plemental intravenous opioids. The one prolonged postopera-
tive in-hospital stay was not related to the procedure, and all 
32 patients were discharged home. 
One year after the procedure
One year after the procedure, 30 patients showed up for 
follow-up visit. Three patients modified significantly the pre-
scribed antihypertensive treatment and were excluded from 
the one year analysis. All other patients remained compliant 
with baseline pharmacotherapy. 
The mean value of systolic BP for the 27 patients ranged 
from 111 to 203 mm Hg (mean value 150.49 mm Hg) and was 
24.42 mm Hg lower than baseline, (p < 0.05). The mean value 
of diastolic BP for the 27 patients ranged from 63 to 117 mm Hg 
(mean value 89.08 mm Hg) and was 10.65 mm Hg lower 
than baseline before the ablation procedure, p < 0.05. The 
pulse pressure decreased to 61.41 mm Hg (mean value) from 
baseline 75.19 mm Hg, p < 0.05. Systolic, and diastolic BP 
and pulse pressure were statistically significantly lower than 
at baseline. The highest mean BP reduction was: systolic 
77.33 mm Hg, diastolic 45 mm Hg (p < 0.05).
The mean values of heart rate ranged from 60 to 121 bpm 
(mean value 77.36 bpm) during the one-year follow-up. The 
mean heart rate was 5.05 bpm higher than that measured 
before the procedure (statistically not significant). No compli-
cations related to the ablation procedure nor adverse events 
were noted. The weight one year after the procedure ranged 
from 58 to 140 kg (mean value 90.52 kg) and was not statisti-
cally different from the mean value before the procedure.
One year after the procedure in 30% (eight patients) sys-
tolic BP was ≤ 140 mm Hg and in 52% (14 patients) diastolic 
BP was ≤ 90 mm Hg. Optimum BP value ≤ 140/90 mm Hg 
was observed in 19% of all patients. 
Additionally, all patients had a computed tomography 
(CT) scan performed to check for the renal artery lesions 
postoperatively. None of the patients who had a CT scan per-
formed in 6–12 months of follow-up had significant lesions in 
renal arteries diagnosed. Two patients had up to 30% lesions in 
their renal arteries, but these lesions were already diagnosed 
during the preoperative angiography. No progress of any of 
these lesions was found in one-year follow-up.
Two years after the procedure
Two years after the procedure, 27 patients were seen in 
follow-up. All patients remained compliant with baseline phar-
macotherapy. There were no reports of adverse clinical events 
related to the procedure or BP changes. Another five patients 
had substantial modification of medication or those not compli-
ant to pharmacotherapy, so they were excluded from the study 
according to the protocol approved by the Ethical Committee.
The mean value of systolic BP for the 27 patients ranged 
from 117 to 192 mm Hg (mean value 146.78 mm Hg) and was 
28.14 mm Hg lower than baseline, p < 0.005. The mean value 
of diastolic BP for the 27 patients ranged from 71 to 110 mm Hg 
(mean value 87.14 mm Hg) and was 12.59 mm Hg lower 
than baseline before the ablation procedure, p < 0.005. The 
pulse pressure decreased to 59.64 mm Hg (mean value) from 
baseline 75.19 mm Hg (Fig. 1), p < 0.05. Systolic, diastolic 
Figure 1. Mean systolic, diastolic blood pressure (BP), and pulse pressure at baseline and one, three, six, nine, 12, 18, and 
24 months after the procedure. All results are statistically significantly (p < 0.05)
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BP, and pulse pressure were statistically significantly lower 
than at baseline. The highest mean BP reduction was: systolic 
83 mm Hg, diastolic 49.67 mm Hg. 
The mean values of heart rate ranged from 57 to 121 bpm 
(mean value 82.96 bpm) during the two years of follow-up. 
The mean heart rate was 9.81 bpm higher than that meas-
ured before the procedure. All these results were statistically 
significant (p < 0.005).
Two years after the procedure, in 30% (eight patients) 
systolic BP was ≤ 140 mm Hg and in 67% (18 patients) 
diastolic pressure was ≤ 90 mm Hg. Optimum BP values 
≤ 140/90 mm Hg were observed in 30% of all patients. 
DISCUSSION
These long-term results are consistent with previous reports 
[11, 13]. Radiofrequency renal nerve ablation is an effec-
tive treatment in reducing the level of BP in patients with 
arterial hypertension resistant to pharmacotherapy. In the 
carefully selected group of patients from Poland, systolic, 
diastolic, and pulse pressure were statistically significantly 
lower two years after the procedure. Also, the complete 
group of SYMPLICITY HTN-1 patients after two years 
follow-up showed that mean systolic and diastolic BP 
remained lowered (p < 0.001) [9].
Radiofrequency renal sympathetic denervation is a safe 
and effective treatment option for patients with drug-resistant 
hypertension. In the first clinical trials, the SIMPLICITY I 
(two-year follow-up) showed mean systolic BP reduction of 
30 mm Hg and diastolic BP of 14 mm Hg, and the SIMPLICITY II 
(one-year follow-up) showed mean systolic BP reduction of 
28.1 mm Hg and diastolic BP of 9.7 mm Hg (p < 0.001). 
After one year observation, both trials showed that durable 
BP reduction was present in 84% of patients [9, 10]. It sug-
gests, that radiofrequency renal ablation may reduce the total 
cardiovascular risk in patients with resistant hypertension ac-
cording to the cardiovascular risk observed in non-resistant 
hypertension patients. The obvious BP lowering, especially the 
pulse pressure, can reflect future risk benefit for these patients; 
however, it is still too early to estimate the overall outcome of 
adverse events such as death, stroke, and myocardial infarc-
tion in long-term observation in this small study. Nonetheless, 
the patients enrolled had exhausted alternative therapy, and 
RN provided a calculable benefit in this cohort. The current 
reports do not report serious adverse events of the RN, but 
few minor complications are noted: pseudoaneurysms in the 
access site, rapid onset hypotonia, urinary tract infections, 
paraesthesia, and pain, all self-limited complications [12]. 
It should be emphasised that meta-analysis supports a 13% 
reduction of mortality for every 10 mm Hg reduction of systolic 
BP [15]. In our group, the BP reduction was persistent in two 
years of follow-up.
To date, no long-term vascular or renal complications 
have been identified in large cohorts, or in our group of 
patients. Also, no new reports of renal failure, renal artery 
stenosis, syncope, or other vascular or cardiovascular adverse 
events were noted during two years of follow-up in the Pol-
ish sample. 
The study, which was conducted to confirm the positive 
role of RN was called SYMPLICITY HTN-3; however, the 
results did not demonstrate sufficient effectiveness of this 
procedure in lowering BP [16]. The study showed no signifi-
cant reduction in BP monitoring, both office measurement 
and 24-h ambulatory blood pressure monitoring (AMBP), in 
the population of patients who underwent RN compared 
with the control group (a placebo sham operated group, who 
received only arteriography of renal arteries). The results of 
SYMPLICITY HTN-3 were critically analysed, especially since 
the reverse results of the Global Simplicity Registry and the 
first meta-analysis of European studies were published [17]. All 
of this questioned denervation of the renal arteries as a step 
forward in the treatment of resistant hypertension. Also, our 
current analysis is at odds with the results of the SYMPLICITY 
HTN-3 study. 
There are many hypotheses trying to explain the reasons 
for the discrepancy between study results. The simplest is that 
in SYMPLICITY HTN-3 patients improved the compliance both 
in terms of lifestyle changes and pharmacotherapy. However, 
it seems that the main reason for the negative results of SYM-
PLICITY HTN-3 was probably the different patient population 
including 25% African Americans, who showed in subgroup 
analysis that they did not respond to renal denervation [18].
It is also believed that in some cases, the procedure 
was not effective because of poor catheter construction (the 
system has been changed now) and little experience of the 
operators. In all discussions, it is also emphasised that the 
crucial point of successful RN is proper patient selection and 
exclusion of patients who simply do not take hypertensive 
drugs [19]. Our patient population was very carefully selected 
from individuals with drug resistant hypertension confirmed 
for years. Also, all patients without proper compliance were 
excluded from the study. 
Based on the HTN-3 study and other known studies 
on RN, we can estimate that this method can be effective 
in a population of Caucasians, under the age of 60 years, 
without renal insufficiency, and with resistant hypertension 
treated obligatorily with four antihypertensive drugs, including 
aldosterone antagonist. In addition, renal denervation should 
be performed with more technologically advanced catheters 
than those used in the study HTN1-3 [19].
Additional positive effects of RN should support the posi-
tive role of this method in advanced patient care. Witkowski et 
al. [20] suggested that renal sympathetic denervation may be 
a potentially useful option for patients with comorbid resist-
ant hypertension, glucose intolerance, and obstructive sleep 
apnoea. Schlaich et al. [21] performed renal denervation in 
obese and hypertense women with polycystic ovary syndrome 
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(PCOS). In this study, renal denervation caused a reduc-
tion in both BP and insulin resistance, which are important 
therapeutic targets in PCOS patients. Improvement of glucose 
tolerance has also been confirmed by other authors [22, 23]. 
Renal denervation in patients with arterial hypertension also 
led to improvement of cardiac diastolic function, reduction 
of left ventricular mass [24], and reduction of augmentation 
index [25] in hypertension patients. Another group of patients 
in whom renal denervation can be a potential therapeutic 
option are haemodialysis patients with resistant or difficult 
to control hypertension. Performed studies showed that renal 
denervation significantly reduces BP in haemodialysis patients 
[26, 27]. Unfortunately, in our group of patients, this kind of 
sub-analysis was not performed.  
Another study performed on a Polish population is 
the Polish Renal Denervation registry [28]. In this study at 
12-month follow-up the mean 24-h systolic BP change was 
–8.3 mm Hg at six months and –4.6 mm Hg at 12 months. This 
registry, similarly to our findings, demonstrated moderate BP 
decrease after RN; however, in both studies the selection of the 
patients was performed very carefully. Findings from both studies 
suggest that in the Polish patient population RN can be effective.
Renal sympathetic denervation, as a new method of 
hypertension treatment, deserves attention because there is 
enough data suggesting it can significantly lower BP in a care-
fully selected group of patients, and this effect is persistent in 
two years of follow-up. 
Limitations of the study
This is a non-randomised, single-arm study with a relatively 
small patient sample size, which does not allow us to come 
to definitive conclusions for the general Polish population.
The study is a sub-analysis of two Polish cohorts of the 
SYMPLICITY I and SYMPLICITY II studies. Patients who were 
not compliant were excluded from the study, but we were not 
able check other patients’ compliance. As was already men-
tioned, six applications per artery (according to the protocol) 
was probably not sufficient to reach perfect results of RN. 
Probably better catheter construction, which facilitates the 
electrode apposition and energy delivery into the arterial wall, 
will also eliminate the problems observed in unexperienced 
operators, associated with difficult anatomy of the artery, and 
decrease the total time of the procedure.
CONCLUSIONS
Renal sympathetic denervation is a safe and effective thera-
peutic treatment reducing the level of BP in patients with 
arterial hypertension resistant to pharmacotherapy. After 
two years of the procedure, no new or late complications or 
unexpected adverse events were noted in the Polish cohort 
of patients. The significant BP reduction after two years of 
follow-up was confirmed, with the BP below 140/90 mm Hg 
in 30% of cases and diastolic BP below 90 mm Hg in 67%.
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Ablacja zakończeń nerwowych w tętnicy nerkowej 
prądem o wysokiej częstotliwości
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Magdalena Bartuś3, Artur Dziewierz4, Stanisław Bartuś4, Wojciech Zajdel2, Dhanunjaya Lakkireddy5
1Klinika Kardiochirurgii i Transplantologii, Uniwersytet Jagielloński, Szpital im. Jana Pawła II, Kraków
2Klinika Kardiologii, Uniwersytet Jagielloński, Szpital im. Jana Pawła II, Kraków
3Zakład Farmakologii Eksperymentalnej, Uniwersytet Jagielloński, Kraków
4II Klinika Kardiologii, Uniwersytet Jagielloński, Szpital Uniwersytecki, Kraków
5The University of Cansas, Cansas City, Stany Zjednoczone
S t r e s z c z e n i e
Wstęp: Nadciśnienie tętnicze jest jedną z najbardziej powszechnych chorób przewlekłych w krajach zachodnich i dotyczy 
więcej niż 25% dorosłej populacji. 
Cel: Celem pracy była ocena zmian ciśnienia tętniczego (BP) u pacjentów z nadciśnieniem tętniczym po ablacji zakończeń 
nerwowych w tętnicach nerkowych z zastosowaniem prądu o wysokiej częstotliwości w 24-miesięcznej obserwacji. 
Metody: Trzydziestu dwóch pacjentów z rozpoznanym nadciśnieniem opornym (20 mężczyzn i 12 kobiet) poddano przez-
skórnej denerwacji zakończeń nerwowych w ścianie tętnic nerkowych. Średnia wartość ciśnienia krwi przed ablacją wynosiła 
[mm Hg]: 174,92 (skurczowe), 99,73 (rozkurczowe), a ciśnienie tętna — 75,19. Po 24 miesiącach obserwacji stwierdzono 
zmniejszenie wartości ciśnienia tętniczego [mm Hg]: skurczowe — 146,78; rozkurczowe — 87,14, ciśnienie tętna — 59,64. 
Wyniki: Wszystkie wyniki były statystycznie znamienne. U 30% pacjentów zanotowano wartość skurczowego BP  
≤ 140 mm Hg, u 67% osób rozkurczowe BP wynosiło ≤ 90 mm Hg, natomiast optymalne wartości ciśnienia krwi  
(≤ 140/90 mm Hg) stwierdzono u 30% pacjentów po 24 miesiącach od ablacji tętnic nerkowych.
Wnioski: W grupie badanych chorych przezskórna ablacja tętnicy nerkowej skutecznie obniżyła skurczowe i rozkurczowe 
BP oraz ciśnienia tętna. Nie stwierdzono istotnych zdarzeń niepożądanych w ciągu 24-miesięcznej obserwacji. Wyniki badań 
polskiej grupy pacjentów nie odbiegają w żaden sposób od wyników uzyskanymi w badaniach SIMPLICITY I i II.
Słowa kluczowe: nadciśnienie tętnicze, ablacja tętnic nerkowych
Kardiol Pol 2017; 75, 9: 899–906
Adres do korespondencji:
prof. dr hab. n. med. Stanisław Bartuś, II Oddział Kliniczny Kardiologii oraz Interwencji Sercowo-Naczyniowych, Szpital Uniwersytecki w Krakowie,  
ul. Kopernika 17, 31–501 Kraków, e-mail: mbbartus@cyf-kr.edu.pl
Praca wpłynęła: 25.10.2016 r. Zaakceptowana do druku: 19.04.2017 r. Data publikacji AoP: 18.05.2017 r.
